Patents

RPS tests improve the health and well-being of patients worldwide by providing an accurate and timely diagnosis, leading to more efficacious medical decisions. The company’s innovative technology platform provides the foundation for its family of novel rapid diagnostic tests. Explore the table below to find out which U.S. patents relate to each RPS product.

 

Product Patents
AdenoPlus® 8,647,890; 8,614,101;
7,723,124; 6,514,773
InflammaDry® 8,647,890; 8,614,101;
7,723,124; 6,514,773

 

Other international and pending patents may apply.